Celgene Corp. (CELG)

95.30
0.56 0.59
NASDAQ : Health Technology
Prev Close 94.74
Open 94.76
Day Low/High 94.72 / 95.44
52 Wk Low/High 58.59 / 98.97
Volume 731.21K
Avg Volume 4.16M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 66.13B
EPS 5.70
P/E Ratio 12.78
Div & Yield N.A. (N.A)

Takeaways and Observations

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters.  I covered last evening's Procter & Gamble short for a profit.  "For Traders Only."...

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Some tried-and-true indicators show what's really going on with the market.

Takeaways and Observations

  Fear and doubt seem to have abandoned Wall Street.  Dr. Hussman, while very much perma-bear, makes some good points in his weekly market commentary. See boldface.  As does my pal Sir Mark Grant on CNBC's Squawk Box.  I have reduced my large SPRD G...

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Trump Investing: Listen, Don't Overreact

Trump Investing: Listen, Don't Overreact

Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.

My Takeaways and Observations

We are likely in a Trump-centric investment world in 2017.   My theme that the president will make market volatility and uncertainty great again, continues.    Consider the contrary, Part Deux.    Mo' gold and I will accumulate under any weakness go...

My Takeaways and Observations

Risk happens fast.    Is the presidential honeymoon over? One of the 10 questions I asked myself today.    "The Return of the Orange Swan?"    Has Boca Biff done it again? Another top call?    Ten questions. In particular, read my comments on Steve ...

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

My Takeaways and Observations

"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...

Three Health-Care Growth Plays

Three Health-Care Growth Plays

Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.

My Takeaways and Observations

The market pushed back presumably after it digested the inaugural speech and absorbed the marches around the world.   I don't believe the new president will be market and economy friendly.    The reflation trade is in question today.  And I remain b...

5 Reasons Why Celgene Should Buy Competitor Biogen

5 Reasons Why Celgene Should Buy Competitor Biogen

There are several reasons why Celgene should buy Biogen.

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

A merger would be smart, profitable ... and attention-grabbing.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

Celgene Ups Revenue and Profit Projections for 2017, but Stock Falls

Celgene Ups Revenue and Profit Projections for 2017, but Stock Falls

Celgene executives have raised guidance for the year, but the stock retreated Monday.

JP Morgan Healthcare Conf.

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer breaks down why it is so difficult to buy drug stocks right now.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

My Takeaways and Observations (3:30 p.m. Edition)

The markets started the day like Usain Bolt at the start of a 100-meter race. But, unlike Bolt, the finish wasn't as strong as the start.   I thought one of the day's features was the reversal in bond yields, particularly after the good data.    The...

My Takeaways and Observations

"Who you tryin' to get crazy with, 'ese? Don't you know I'm loco?..." -- Cypress Hill, Insane in the Brain 2017 will be the year of "The Dude."    My favorite large-cap long Allergan  and short Caterpillar   for next year.  AGN closed up by $4(!) wh...

My Top Pick for 2017: Short QQQ

My Top Pick for 2017: Short QQQ

Six reasons why the Nasdaq 100 ETF seems ready to pull back.

My Top Pick for 2017: Short QQQ

My trade of the year for 2017 is to short the PowerShares QQQ Trust ETF , which tracks the Nasdaq 100 index. Here's my investment thesis for this play: The Nasdaq 100 Already Has Rallied QQQ already has risen from about $96 a share at the market's F...

My Takeaways and Observations (3 p.m. Edition)

Is it Friday, yet? My annual tribute to "El Capitan."    Tech drek?!!!???!    Hope? Nope! (1) Part 1 (2) Part II (3) Part III   Palm Beach Chronicles (Issue #2 Supplement)    You know what I am shorting; here is what I am buying.    Stocks meandered...

My Takeaways and Observations

"Be true to your teeth so they won't be false to you." -- Soupy Sales Have we entered a post-fact investment world?    I moved to large ProShares UltraShort S&P500 ETF   position as my freak flags show again. Viva La Revolucion!    Good stuff from t...

My Takeaways and Observations

More of the same -- as Mr. Market remains enthusiastic with The Orange Swan and his contemplated policies aimed at catalyzing domestic economic growth.   But, with fear and doubt having left Wall Street, we may be reaching The Outer Limits. And I ha...

Expect Some Big-Cap Biotech Love in 2017

We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...

2 Biotech Giants Poised for a Better 2017

2 Biotech Giants Poised for a Better 2017

Here's why Gilead and Celgene should finally reward their shareholders next year.

My Takeaways and Observations

"Everyone here likes the bounce." -- President-elect Donald Trump (said in a meeting today at Trump Tower with tech executives) A good day for the ursine crowd but not so good for the bullish cabal as they had a bad day -- for a change. (Yes, I am w...